Genetesis

In about 3 minutes, I had a full cardio scan and report in hand...amazing and disruptive life science technology...grateful for our elected officials like Rep. Adam Mathews  who are curious to learn more about the life-changing products that Ohio Life Sciences companies like Genetesis are developing all over this state! Amazing work Peeyush Shrivastava Ryan Yoo ☁️Vineet Erasala Manny Setegn

Cheers to PI Dr. Dany Jacob, Dana King, Eric Burgett, Hall Jamie, and the rest of the MICRO2 study team at Saint Luke's Health System on enrolling their first MICRO2 patient! Prior to the initiation of the MICRO2 trial, the recently published MICRO trial demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) in the space of a 90-second, no-contact scan - a first-of-its-kind exploration in what is now six decades of research into MCG. In contrast, the current gold standard for diagnosis is invasive coronary functional angiography, an option which remains practically out-of-reach for a majority of patients who likely suffer from CMD today. Worse still, clinician recognition of CMD and its impact on long-term outcomes remains low, perhaps due in part to the lack of simple, highly accessible options for diagnosis today. We’re excited to partner with clinicians, like Dr. Jacob and the rest of his team, who are actively working to address this unmet need! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

We're excited to continue our recent stream of announcements with the formal publication of results from the MICRO trial! These results represent the first time MCG has been explored for diagnostic use in patients with potential coronary microvascular dysfunction (CMD) and demonstrate MCG's ability to diagnose CMD in a single 90-second, zero-contact scan. "Our explorations thus far into CMD are a symbol of our commitment to demonstrating MCG's utility across the entire spectrum of ischemic heart disease. It's also clear that [...] the need for a fast functional assessment ischemia is perhaps even more important than before," says Dr. Robert Takla, MD, MBA, FACEP, Chief Medical Officer at Genetesis. On the heels of MICRO, Genetesis has already initiated its pivotal MICRO2 trial, powered to validate the findings from MICRO and intended to be FDA-facing in support of a De Novo submission next year. Read the full announcement here: https://lnkd.in/gDQFhWem

Kudos to PI Dr. Khaled Ziada, along with Rachel Landis, Kelly Norris, Douglas Eckley, Danielle Kellner, Stephanie Stoianoff, Loretta Winstead, Mark Majchszak, Meghan Khebouz, and the entire MICRO2 study team at Cleveland Clinic for enrolling their first patient in the MICRO2 study! Dr. Ziada's first enrollments come on the heels of the formal publication of results from the pilot MICRO trial, where early data demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) with a simple 90-second, zero-contact scan. Dr. Ziada's team was a key contributor to the success of MICRO and now officially kickstarts their contribution to MICRO2, primarily designed to validate these results in a larger cohort of patients. We're thrilled by the opportunity to collaborate with Dr. Ziada and his colleagues as we further important research in both CMD and MCG together! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congratulations to PI Dr. Edouard Daher M.D., FACC, Viviane Kazan, M.D., and the rest of the MICRO2 study team, including Dr. Robert Takla, MD, MBA, FACEP, Dr. Antonious Attallah, MD, FACC, Dr. Ahiwuala and Nader Abdullah at Ascension St. John on enrolling their first MICRO2 patient! This pivotal FDA-facing study aims to validate CardioFlux MCG’s diagnostic ability to detect myocardial ischemia caused by underlying coronary microvascular dysfunction (CMD). Unfortunately, the current standard of care largely fails CMD patients today, many of whom are misdiagnosed or incorrectly told that their symptoms are benign. These patients are predominantly women. We’re excited to partner with Dr. Daher and the rest of his team in solving this critical gap in cardiac care! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

We're thrilled to announce the launch of our groundbreaking clinical trial, MICRO2, which aims to validate early evidence demonstrating MCG’s ability to aid in the noninvasive diagnosis of Coronary Microvascular Dysfunction. Learn more in our press release.

🎊 🏥 Our incredible engineering team is doing it again! ⚒ ✨ We're thrilled to see the progress on installations of CardioFlux MCG at Hackensack Meridian Health and Saint Luke's Health System. Huge congratulations to everyone involved for advancing cardiac imaging and improving patient care! #microvascular #CMD #INOCA #CardioFluxMCG #MICRO2

Off the heels of the successful completion of our MICRO1 and MICRO(T) trials, MICRO2 is a pivotal, FDA-facing study intended to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction (CMD). Today, the vast majority of these patients - most of whom are women and likely do not know their symptoms are due to CMD - are either misdiagnosed or almost entirely ignored under the current standard of care, despite the fact that research has consistently demonstrated CMD's significant impact on both a patient's quality of life AND their long-term prognosis. MICRO2 will compare CardioFlux MCG's diagnostic performance against the current industry gold standard of invasively measured Coronary Flow Reserve, and if successful, could represent evidence of the first zero-contact, zero-radiation diagnostic option for patients suffering from this condition. Our team expects to ramp patient enrollment across the next several weeks and anticipates a first read-out of results in Q1 of 2025. Congratulations to both our team at Genetesis and our incredible clinical partners on the first of what are hopefully many MICRO2 milestones! #microvascular #CMD #INOCA #CardioFluxMCG #MICRO2

🔍 Calling All EKG Technicians in the Mason/Cincinnati Area! 🔍 Are you an experienced EKG Technician looking to shape the future of healthcare technology? We're looking for individuals with 2+ years of experience to participate in testing our next-gen device! As a participant, you'll have the opportunity to provide valuable feedback on the usability & functionality of cutting-edge cardiac diagnostic technology. Your insights will directly impact the development of a product aimed at revolutionizing cardiac care. Contact zoe.storch@genetesis.com for more information about time and compensation.

For this week's Forbes 30 Under 30 Newsletter, I spoke with the cofounders of Genetesis, a Cincinnati-based biotech company. The biggest takeaway from our conversation? Rely on those around you to grow. The three childhood friends came together in 2013 with a mission to make it easier (and more accurate) to get a diagnosis at the doctors office, with a special focus on cardiology. They're backed by $40 million from investors like Mark Cuban today, but it took years of working with local medical experts, conducting tests with their technology on friends and family, and participating in local pitch competitions and entrepreneurship groups to finalize their proof of concept. Read more about their journey from high-school founders to the Forbes 30 Under 30 list and $40 million in funding here. *Do you know someone else from the Cincinnati area making waves in their industry? We're looking for young founders and leaders for this year's 30 Under 30 Local Cincinnati list. Let us know if you have any nominations by emailing u30lister[at]forbes[dot]com with their name and bio today.* https://lnkd.in/ehH-sbn3 Peeyush Shrivastava, Manny Setegn, Vineet Erasala